Optimal management for initially diagnosed Ta high grade bladder cancer. What does matter for intravesical recurrence?

Tetsuya Shindo,1,2 Atsushi Takahashi,1 Kohel Hashimoto,1 Toshiaki Tanaka,1 Keisuke Taguchi,2 Naoki Itoh,1 Manabu Okada,1 Hiroshi Hotta,1 Yasuyasu Kunishima,1 Iizuka Hirose,1 Masanori Matsukawa,2 Hitoshi Tachiki,2 Ryusuke Kato,1 Shiro Hinotsu,3 Naoya Masumori,1

[1]Dept. of Urology, Hokkaido Goryoukaku Hospital, 2 Sapporo Medical University Urologic Oncology Consortium, Dept. of Biostatistics, Sapporo Medical University, Sapporo, Japan,

Objectives: The aim of this study were to evaluate the oncological outcome and impact of each treatment affecting intravesical recurrence in patients who newly diagnosed Ta high grade (TaHG) non-muscle invasive bladder cancer (NMIBC).

Methods: We retrospectively evaluated TaHG bladder cancer patients who newly diagnosed by transurethral resection (TUR) from January 2007 through October 2018 in the Sapporo Medical University Urologic Consortium. Primary endpoint was intravesical recurrence and secondary endpoint was treatment options affecting intravesical recurrence. We excluded patients having prior history of bladder cancer. Tumor grade was determined according to 1973 WHO and 2004 WHO/ISUP grading system.

Results: We included 390 patients, with a mean age of 73 years. Mean follow up period was 30.5 months after TUR. Of them, 111 patients (28.5%) experienced intravesical recurrence. Second TUR was performed for 255 patients (65.4%) and immediate intravesical chemotherapy was done for 167 patients (42.8%). Two-hundred sixty patients (66.7%) underwent induction intravesical instillation therapy. Two-year recurrence free survival rate was 76.2%. According to multivariate analysis, treatment options reducing intravesical recurrence risk were immediate intravesical instillation and induction intravesical instillation therapy (P = 0.003, P = 0.03, respectively). Contrarily, second TUR did not impact on intravesical recurrence (P = 0.12).

Conclusions: Approximately one-third of the patients with newly diagnosed TaHG bladder cancer developed intravesical recurrence during 3 years. Immediate and induction intravesical chemotherapy were critical management to reduce the risk of intravesical recurrence.

Aim
- To evaluate appropriate treatment option for reducing intravesical recurrence in newly diagnosed TaHG bladder cancer.

Patients and Methods
- Patients who newly diagnosed TaHG bladder cancer.
- Period: From January 2007 through October 2018
- Design: Multicenter retrospective study
- Institutional review board number 302-162

Exclusion criteria
- Prior history of bladder cancer.
- Radiographically suspicious of muscle invasive bladder cancer.

Table 2. Risk factors affecting intravesical recurrence according to treatment options

<table>
<thead>
<tr>
<th>Treatment Options</th>
<th>Univariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate instillation (Yes)</td>
<td>0.58 (0.43-0.80)</td>
<td>0.034</td>
</tr>
<tr>
<td>Induction instillation (Yes)</td>
<td>0.56 (0.39-0.82)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

To determine treatment option reducing intravesical recurrence in TaHG NMIBC patients, we performed univariate and multivariate analysis (table 2). Accordingly, immediate intravesical instillation of THP and induction intravesical treatment including THP, MMC, and BCG statistically decreased intravesical recurrence. In contrast, second TUR did not achieve statistical power for reducing intravesical recurrence in the cohort.

Figure 1. Intravesical recurrence free survival rate of all patients.

Figure 2. Intravesical recurrence free survival rate according to the risk classification.

We classified the patients according to the risk for intravesical recurrence from the aspect of treatment options. The risk factors were no immediate intravesical instillation and no induction intravesical treatment. Patients with 2 risks were categorized as Poor risk, 1 risk factor as intermediate risk, no risk factor as favorable risk group. Figure 2 shows intravesical recurrence free survival according to the risk model (Log-rank test, P < 0.001).

Conflict of Interest
The authors have nothing to disclose.